Clinical trials: Immune Responses, open to volunteers
Mpox (Monkeypox)
Assessment of Immune Memory - Humoral and Cellular - in mPOX-infected Patients : an Ancillary Study of the ANRS0258s MOSAIC Cohort
Primary objective The overall objective is to assess the long-term amplitude and durability of the immune responses after mpox virus (MPXV) infection.
- Trial name
- POXAIM (NCT07592429)
- Testing
- blood sampling
- Volunteers
- 60 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Human Anaplasmosis
Epidemiological, Clinical and Biological Characteristics of Human Anaplasmosis Cases in Alsace
Anaplasmosis is a bacterial infection caused by the intracellular bacterium Anaplasma phagocytophilum and transmitted by ticks. This bacterium is present in approximately 1% of ticks in Alsace.
- Trial name
- ANARETRO (NCT07312474)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Activity, Motor, Biomarkers
Comparison of the Effects of Aerobic-Anaerobic Exercises on Hormonal and Immune Biomarkers
This study aims to compare the effects of aerobic and anaerobic exercise on hormonal, immunological, and metabolic biomarkers in young individuals using blood and saliva samples.
- Conditions
- Activity, Motor, Biomarkers, Exercise, Immunity
- Trial name
- Biomarkers (NCT07092969)
- Testing
- Treadmill Exercise, Bicycle Exercise
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sakarya Applied Sciences University
Kaposi Sarcoma
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Background: Kaposi sarcoma (KS) is a cancer that causes abnormal tissue to grow in the skin, lymph nodes, and other organs. KS is caused by a virus known as Kaposi sarcoma herpesvirus.
- Trial name
- NCT07308886
- Testing
- CYT107
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer Stage III
Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Stage III NSCLC
Improving personalized cancer treatments and finding the best strategies to treat each patient relies on using new diagnostic technologies.
- Trial name
- MRD-LUNG (NCT06111807)
- Testing
- ctDNA
- Where
- 6 sites in France, Germany and 1 more
- Volunteers
- 248 people
- Sponsor
- University Medical Center Groningen
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
INfections in Patients Treated With CAR-T
This study includes adults with multiple myeloma or B-cell lymphoma who were/will be treated with CAR-T cell therapy at the IRCCS Azienda Ospedaliero-Universitaria di Bologna.
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma, B-Cell Non-Hodgkin Lymphoma, Bloodstream Infections
- Trial name
- IN-CART (NCT07713511)
- Where
- Italy
- Volunteers
- 290 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Non Small Cell Lung Cancer, Healthy
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
The goal of this exploratory study is understand the mechanisms of response to immunotherapy in Non-Small Cell Lung Cancer patients.
- Trial name
- PROPHETIC (NCT05736029)
- Testing
- blood, stool and tissue samples collection
- Where
- United States
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- OncoHost Ltd.
Arthritis, Rheumatoid Arthritis (RA)
Dose Response of Exercise for Arthritis Management
The purpose of the study is to see examine the effects of 3 different levels of physical activity (45 minutes/week, 90 minutes/week, or 150 minutes/week) on arthritis symptoms.
- Conditions
- Arthritis, Rheumatoid Arthritis (RA), Gout, Fibromyalgia (FM)
- Trial name
- DREAM (NCT06880653)
- Testing
- DREAM Adaptive Intervention
- Where
- United States
- Volunteers
- 285 people
- Sponsor
- University of South Carolina
Sepsis, Immunologic Paralysis
Immune Homeostasis in Sepsis and Septic Shock
Detailed description of immune response and its dynamics in sepsis and septic shock patiens by means of transcriptomics, flow-cytometry and cytokine analysis.
- Conditions
- Sepsis, Immunologic Paralysis, Immunologic Suppression, Immune Deficiency
- Trial name
- IMHOTEP (NCT04448951)
- Testing
- transcriptomics, flow-cytometry, cytokines
- Where
- Czechia
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Charles University, Czech Republic
Lymphoma
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
To learn if response-adapted, ultra-low dose radiation therapy can help to control MZL. This means participates first receive lower does of radiation therapy and then, based on how the disease responds, may receive higher doses…
- Trial name
- NCT05929612
- Testing
- Ultra Low Dose 4 Gy Radiation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
AIDS Pneumonia, Septic Shock
Clinical Application of Cytokine Adsorption Technique in AIDS Patients With Severe Pneumonia and/or Septic Shock
Observing the Real-World Application Effectiveness of Cytokine Immune Adsorption Technology in AIDS Patients with Severe Pneumonia or septic shock.
- Trial name
- NCT06145828
- Testing
- Cytokine Adsorption
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangzhou 8th People's Hospital
Cervical Cancer Prevention
Study on the Safety, Humoral Immune Response, and Memory B Cell Response Characteristics of Sequential 9-Valent HPV Vaccination
This is a single-center, prospective, open-label, partially randomized, matched-controlled trial designed as a cohort study. The study plans to enroll 360 healthy female participants aged 18 to 45 years, divided into three…
- Trial name
- NCT07530679
- Testing
- 9-valent HPV vaccination at months 0 and 6, 9-valent HPV vaccination at months 0 , 1 and 6
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Lymphoma, Hodgkin Lymphoma
Early Assessment of Lymphoma Treatment Response Using Phased Variant Analysis With Next-Generation Sequencing
Lymphoma is a prevalent lymphoid malignancy globally and in Taiwan. Large B-cell lymphoma (LBCL) is the most common subtype of aggressive B-cell lymphoma.
- Conditions
- Lymphoma, Hodgkin Lymphoma, T-cell Lymphoma, Waldenstrom Macroglobulinaemia
- Trial name
- NCT06550427
- Testing
- ctDNA analyzed by phased variant
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Myocardial Injury, Atherosclerosis Cardiovascular Disease
Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study)
Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart.
- Conditions
- Myocardial Injury, Atherosclerosis Cardiovascular Disease, Cardiac Imaging Techniques, Genetics
- Trial name
- OXAMI (NCT07772570)
- Testing
- blood sampling, Intracoronary Imaging, Cardiovascular Magnetic Resonance Imaging
- Where
- United Kingdom
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Lymphoma, Follicular Lymphoma
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
This research is being done to see if epcoritamab is effective in treating follicular lymphoma as a second line of treatment. The name of the study drug in this research study is: -Epcoritamab (a type of antibody)
- Conditions
- Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
- Trial name
- NCT06510361
- Testing
- Epcoritamab
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Beth Israel Deaconess Medical Center
Asthma, COPD
Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -
The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections.
- Conditions
- Asthma, COPD, Bacterial Pneumonia, Viral Pneumonia
- Trial name
- OXIGENE (NCT07386912)
- Testing
- Characterization of the neutrophil granulocyte epigenome, Characterization of the T-cell immune response to to various oxidatively modified mycobacterial antigens
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Research Center Borstel
Cutaneous Squamous Cell Carcinoma (CSCC)
Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans, it exhibits a high tumor mutational burden and is more common in immunocompromised patients, which aimed to explore the impact of…
- Trial name
- NGF-GRACE (NCT07064330)
- Testing
- Cemiplimab
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Lupus Nephritis (LN)
Neutrophil Extracellular Traps and Lupus Nephritis
Lupus Nephritis is one of the most severe organ manifestations of systemic lupus erythematosus and represents a major cause of morbidity, chronic kidney disease, and long-term mortality.
- Trial name
- NCT07721857
- Testing
- Serum Neutrophil Extracellular Traps
- Volunteers
- 100 people
- Sponsor
- Assiut University
Multiple Sclerosis (MS) - Relapsing-remitting
Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis
The purpose of the research study is to explore new retinal imaging biomarkers of immune cell activity in MS during use of ublituximab (Briumvi) treatment.
- Trial name
- NCT06864936
- Testing
- Ublituximab, Other disease modifying therapies
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Maryland, Baltimore
NSCLC (Non-small Cell Lung Cancer)
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
his multicenter, open-label, single-arm phase I/II trial will evaluate the safety, tolerability, and preliminary efficacy of oral paclitaxel solution combined with an immune checkpoint inhibitor and concurrent stereotactic body…
- Trial name
- NCT07754812
- Testing
- Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT)
- Where
- 5 sites in China
- Volunteers
- 78 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China